Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 6:37:13886.
doi: 10.3389/ti.2024.13886. eCollection 2024.

Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus

Affiliations

Desensitization With Imlifidase for HLA-Incompatible Deceased Donor Kidney Transplantation: A Delphi International Expert Consensus

Lucrezia Furian et al. Transpl Int. .

Abstract

Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor-recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.

Keywords: HLA incompatible; HLAi; desensitization; imlifidase; kidney transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
The six sections of the Delphi questionnaire that evaluated the various aspects of kidney transplantation and the utilization of imlifidase.
FIGURE 2
FIGURE 2
Visual abstract.

Similar articles

Cited by

References

    1. De Ferrante H, Smeulders B, Tieken I, Heidt S, Haasnoot GW, Claas FHJ, et al. Immunized Patients Face Reduced Access to Transplantation in the Eurotransplant Kidney Allocation System. Transplantation (2023) 107(10):2247–54. 10.1097/TP.0000000000004687 - DOI - PubMed
    1. Habal MV, Farr M, Restaino S, Chong A. Desensitization in the Era of Precision Medicine: Moving from the Bench to Bedside. Transplantation (2019) 103(8):1574–81. 10.1097/TP.0000000000002737 - DOI - PubMed
    1. Jackson KR, Holscher C, Motter JD, Desai N, Massie AB, Garonzik-Wang J, et al. Posttransplant Outcomes for cPRA-100% Recipients under the New Kidney Allocation System. Transplantation (2020) 104(7):1456–61. 10.1097/TP.0000000000002989 - DOI - PMC - PubMed
    1. Schinstock CA, Smith BH, Montgomery RA, Jordan SC, Bentall AJ, Mai M, et al. Managing Highly Sensitized Renal Transplant Candidates in the Era of Kidney Paired Donation and the New Kidney Allocation System: Is There Still a Role for Desensitization? Clin Transpl (2019) 33(12):e13751. 10.1111/CTR.13751 - DOI - PubMed
    1. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended Treatment for Antibody-Mediated Rejection after Kidney Transplantation: The 2019 Expert Consensus from the Transplantation Society Working Group. Transplantation (2020) 104(5):911–22. 10.1097/TP.0000000000003095 - DOI - PMC - PubMed